Responses
Clinical/translational cancer immunotherapy
Original research
Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.
